FI92714B - Apolipoprotein-B-specifika monoklonala antikroppar producerade av två nya hybridomer - Google Patents
Apolipoprotein-B-specifika monoklonala antikroppar producerade av två nya hybridomer Download PDFInfo
- Publication number
- FI92714B FI92714B FI873410A FI873410A FI92714B FI 92714 B FI92714 B FI 92714B FI 873410 A FI873410 A FI 873410A FI 873410 A FI873410 A FI 873410A FI 92714 B FI92714 B FI 92714B
- Authority
- FI
- Finland
- Prior art keywords
- receptor
- immunoreactant
- apo
- solid
- apoprotein
- Prior art date
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 89
- 102100040202 Apolipoprotein B-100 Human genes 0.000 title description 138
- 101710095342 Apolipoprotein B Proteins 0.000 title description 3
- 108010008150 Apolipoprotein B-100 Proteins 0.000 claims abstract description 138
- 239000000203 mixture Substances 0.000 claims abstract description 80
- 102000006991 Apolipoprotein B-100 Human genes 0.000 claims abstract 3
- 102000005962 receptors Human genes 0.000 claims description 274
- 239000007790 solid phase Substances 0.000 claims description 91
- 102000006410 Apoproteins Human genes 0.000 claims description 76
- 108010083590 Apoproteins Proteins 0.000 claims description 76
- 239000007787 solid Substances 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 65
- 238000003556 assay Methods 0.000 claims description 47
- 210000001124 body fluid Anatomy 0.000 claims description 44
- 239000010839 body fluid Substances 0.000 claims description 44
- 239000003153 chemical reaction reagent Substances 0.000 claims description 40
- 239000007791 liquid phase Substances 0.000 claims description 37
- 230000036046 immunoreaction Effects 0.000 claims description 34
- 238000002156 mixing Methods 0.000 claims description 29
- 239000011159 matrix material Substances 0.000 claims description 28
- 102000004190 Enzymes Human genes 0.000 claims description 22
- 230000002860 competitive effect Effects 0.000 claims description 21
- 108090000790 Enzymes Proteins 0.000 claims description 20
- 210000002966 serum Anatomy 0.000 claims description 19
- 238000004166 bioassay Methods 0.000 claims description 18
- 102000016979 Other receptors Human genes 0.000 claims description 7
- 239000002594 sorbent Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- 239000012071 phase Substances 0.000 claims description 3
- 150000004678 hydrides Chemical class 0.000 claims 1
- 108020003175 receptors Proteins 0.000 description 232
- 102000007330 LDL Lipoproteins Human genes 0.000 description 98
- 108010007622 LDL Lipoproteins Proteins 0.000 description 98
- 210000002381 plasma Anatomy 0.000 description 67
- 239000000523 sample Substances 0.000 description 64
- 230000027455 binding Effects 0.000 description 63
- 238000009739 binding Methods 0.000 description 63
- 239000000427 antigen Substances 0.000 description 40
- 108091007433 antigens Proteins 0.000 description 40
- 102000036639 antigens Human genes 0.000 description 40
- 238000002965 ELISA Methods 0.000 description 39
- 102000018616 Apolipoproteins B Human genes 0.000 description 34
- 108010027006 Apolipoproteins B Proteins 0.000 description 34
- 102000004895 Lipoproteins Human genes 0.000 description 30
- 108090001030 Lipoproteins Proteins 0.000 description 30
- 230000009870 specific binding Effects 0.000 description 28
- 239000011230 binding agent Substances 0.000 description 26
- 230000000890 antigenic effect Effects 0.000 description 25
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 25
- 239000002953 phosphate buffered saline Substances 0.000 description 25
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- 238000003127 radioimmunoassay Methods 0.000 description 24
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 20
- 239000002245 particle Substances 0.000 description 20
- 241000283973 Oryctolagus cuniculus Species 0.000 description 19
- 229940098773 bovine serum albumin Drugs 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 229940088598 enzyme Drugs 0.000 description 19
- 239000002609 medium Substances 0.000 description 18
- 108010001831 LDL receptors Proteins 0.000 description 17
- 102000000853 LDL receptors Human genes 0.000 description 17
- 239000000872 buffer Substances 0.000 description 17
- 210000002950 fibroblast Anatomy 0.000 description 17
- 230000036963 noncompetitive effect Effects 0.000 description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 108010004103 Chylomicrons Proteins 0.000 description 15
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 15
- 239000000499 gel Substances 0.000 description 15
- 101800001976 Apolipoprotein B-48 Proteins 0.000 description 13
- 102400000352 Apolipoprotein B-48 Human genes 0.000 description 13
- 230000015556 catabolic process Effects 0.000 description 13
- 238000006731 degradation reaction Methods 0.000 description 13
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 230000009871 nonspecific binding Effects 0.000 description 13
- 210000003567 ascitic fluid Anatomy 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 208000029078 coronary artery disease Diseases 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 241000283707 Capra Species 0.000 description 10
- 108010010234 HDL Lipoproteins Proteins 0.000 description 10
- 102000015779 HDL Lipoproteins Human genes 0.000 description 10
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 108010032595 Antibody Binding Sites Proteins 0.000 description 9
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 9
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 9
- 238000008214 LDL Cholesterol Methods 0.000 description 8
- 239000000020 Nitrocellulose Substances 0.000 description 8
- -1 cholesteryl ester Chemical class 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 229920001220 nitrocellulos Polymers 0.000 description 8
- 229920000936 Agarose Polymers 0.000 description 7
- 229920001213 Polysorbate 20 Polymers 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 201000000050 myeloid neoplasm Diseases 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 208000035150 Hypercholesterolemia Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000007982 barbital buffer Substances 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 239000012847 fine chemical Substances 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000001155 isoelectric focusing Methods 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 102000013415 peroxidase activity proteins Human genes 0.000 description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 description 5
- 239000004800 polyvinyl chloride Substances 0.000 description 5
- 229920000915 polyvinyl chloride Polymers 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
- 102000013918 Apolipoproteins E Human genes 0.000 description 4
- 108010025628 Apolipoproteins E Proteins 0.000 description 4
- 108010015776 Glucose oxidase Proteins 0.000 description 4
- 239000004366 Glucose oxidase Substances 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 229940116332 glucose oxidase Drugs 0.000 description 4
- 235000019420 glucose oxidase Nutrition 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- 230000000737 periodic effect Effects 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 238000005199 ultracentrifugation Methods 0.000 description 4
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010027070 Apolipoproteins C Proteins 0.000 description 3
- 102000018655 Apolipoproteins C Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000000951 immunodiffusion Effects 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 238000011533 pre-incubation Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 101000889990 Homo sapiens Apolipoprotein(a) Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000005717 Myeloma Proteins Human genes 0.000 description 2
- 108010045503 Myeloma Proteins Proteins 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 229960002319 barbital Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 102000045903 human LPA Human genes 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 238000010185 immunofluorescence analysis Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000013391 scatchard analysis Methods 0.000 description 2
- 238000002764 solid phase assay Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- UYBWIEGTWASWSR-UHFFFAOYSA-N 1,3-diaminopropan-2-ol Chemical compound NCC(O)CN UYBWIEGTWASWSR-UHFFFAOYSA-N 0.000 description 1
- VRCSNYKNBODDIM-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-6-yloxy)-n,n-dimethylethanamine;hydrochloride Chemical compound [Cl-].O1CCOC2=CC(OCC[NH+](C)C)=CC=C21 VRCSNYKNBODDIM-UHFFFAOYSA-N 0.000 description 1
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010024284 Apolipoprotein C-II Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 244000250392 Cardamine diphylla Species 0.000 description 1
- 235000001250 Cardamine diphylla Nutrition 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 description 1
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100174574 Mus musculus Pikfyve gene Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000011365 complex material Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- SOCTUWSJJQCPFX-UHFFFAOYSA-N dichromate(2-) Chemical compound [O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O SOCTUWSJJQCPFX-UHFFFAOYSA-N 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108010094102 enzymobeads Proteins 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 201000003570 spinocerebellar ataxia type 17 Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (19)
1. Hybridom med ATCC-depositionsnummer HB 8746.
2. Receptor, kännetecknad av att den (a) im-munoreagerar med apoprotein B-100, och (b) utsöndras av hybridom med ATCC-depositionsnummer HB 8746.
3. Receptor enligt patentkrav 2, kännetecknad av att den är en intakt antikropp.
4. Hybridom med ATCC-depositionsnummer HB 8742.
5. Receptor, kännetecknad av att den a) immu-noreagerar med apoprotein B-100, och (b) utsöndras av hybridom med ATCC-depositionsnummer HB 8742.
6. Receptor enligt patentkrav 5, kännetecknad av att den är en intakt antikropp.
7. Förfarande för att bestämma mängden av apoprotein B-100 i ett kroppsvätskeprov, kännetecknat av att för-farandet omfattar följande steg: (a) det kroppsvätskeprov som skall bestämmas tas; (b) receptormolekyler produceras i biologiskt aktiv form, vilka (i) immunoreagerar med apoprotein B-100, och som (ii) utsöndras av hybridom med ATCC-depositionsnummer HB 8746 eller hybridom med ATCC-depositionsnummer HB 8742; (c) en känd mängd av nämnda kroppsvästkeprov blandas med en pä förhand bestämd mängd av nämnda receptormolekyl för att bilda en immunoreaktionsblandning; (d) nämnda blandning hälls i biologiska bestämningsförhäl-·: landen under en pä förhand bestämd tid, som med avseende pä receptormolekylerna i blandningen är tillräcklig för att immunologiskt binda apoprotein B-100 som finns i provet, varvid immunoreaktant bildas; och (e) mängden immunoreaktant som bildas i nämnda blandning bestäms. 9271 4
8. Förfarande enligt patentkrav 7, kännetecknat av att nämnda kroppsvätskeprov är antingen plasma eller se-rum.
9. Förfarande enligt patentkrav 7, kännetecknat av att nämnda receptor är en intakt antikropp.
10. Förfarande enligt patentkrav 7, kännetecknat av att kroppsvätskeprovet dessutom prepareras för bestämnin-gen genom att inkludera följande ytterligare steg: (f) biologiskt aktiva andra receptormolekyler produceras, vilka immunoreagerar med apoprotein B-100 som finns i nämnda kroppsvätskeprov, och vilka är rester av vardera receptormo-lekylsatsen, som utsöndras av hybridom med ATCC-depositions-nummer HB 8746 eller hybridom med ATCC-depositionsnummer HB 8742; och (g) en pä förhand bestämd mängd av nämnda andra receptormolekyler blandas med nämnda kroppsvätskeprov, varvid en im-munoreaktionsblandning bildas; (h) nämnda immunoreaktionsblandning hälls i biologiska be-stämningsförhällanden under en pä förhand bestämd tid, som med avseende pä receptormolekylerna i blandningen är till-räcklig för att immunologiskt binda apoprotein B-100 som finns i provet, varvid det bildas lagrad immunoreaktant.
11. Förfarande enligt patentkrav 10, kännetecknat av att nämnda receptor är en intakt antikropp.
12. Förfarande enligt patentkrav 10, kännetecknat av att den förstnämnda receptorn fästes vid en fast matris för att bilda en fast bärare; nämnda andra receptor '· innehäller en stämpel med vars hjälp närvaro av nämnda andra receptor ingäende i immunoreaktanten kan uttryckas; och den i steg (e) bestämda immunoreaktanten är en lagrad immunoreaktant i fast fas, som innehäller nämnda stämpel.
13. Diagnostiskt system för att bestämma mängden av apo-B- 100. ett kroppsprov, kännetecknat av att det omfattar: II 9271 4 (a) ett första biologiskt aktivt, specifikt bundet ämne om-fattande receptormolekyler, vilka (i) immunoreagerar med apoprotein B-100, och (ii) är antingen receptormolekyler utsöndrade av hydridom ATCC HB 8746 eller receptormolekyler utsöndrade av ATCC HB 8742? och (b) ett biologiskt aktivt, stämplat, andra specifikt bundet ämne för att uttrycka den immunoreaktion i vilken nämnda första bundna ämne deltar med apo B-100.
14. Bestämningssystem enligt patentkrav 13, k ä n n e -tecknat av att det stämplade, andra specifikt bundna ämnet omfattar andra receptormolekyler antingen av recepto-rer som utsöndras av hybridom ATCC HB 8746 eller receptorer som utsöndras av hybridom ATCC HB 8742.
15. Bestämningssystem enligt patentkrav 14, k ä n n e -tecknat av att stämpeln är ett enzym.
16. Bestämningssystem enligt patentkrav 13, k ä n n e -tecknat av att nämnda första specifikt bundna ämne är fästat vid en fast matris, varvid en fast bärare bildas.
17. Steril affinitetssorbent, som bildas av biologiskt ak-tiva receptormolekyler som immunoreagerar med apoprotein B-100 och väljs i gruppen bestäende av: . ' (a) receptormolekyler utsöndrade av hybridom HB 8746 (b) receptormolekyler utsöndrade av hybridom HB 8742 och (c) en blandning av receptormolekyler under punkt (a) och (b) ; kännetecknad av att nämnda receptormolekyler är fästade vid en fast matris, varvid en fast bärare bildas. « ♦ •
18. Förfarande för att bestämma apoprotein B-100 som ingär i ett kroppsvätskeprov, kännetecknat av att det omf attar följande steg: (a) det kroppsvätskeprov som skall bestämmas tas? (b) en fast bärare produceras, som bildats av en fast mat-• ris, vid vilken dessutom är fästad i biologiskt aktiv form 9271 4 en första receptor, som reagerar immunologiskt med apoprotein B-100, och som utsöndras av hybridom med ATCC-depositionsnummer HB 8746; (c) en andra biologiskt aktiv receptor produceras, som im-munoreagerar med apoprotein B-100, och som utsondras av hybridom med ATCC-depositionsnummer HB 8742, medan nämnda andra receptor är associerad med ett stämpelenzym med vars hjälp närvaro av nämnda andra receptor kan uttryckas i immunoreak-tanten; (d) väsentligt samtidigt blandas: (i) nämnda kroppsprov; och (ii) nämnda fasta bärare; och (iii) nämnda stämplade andra receptor för att bilda en im-munoreaktionsblandning i fast/västkefas; (e) nämnda blandning hälls i biologiska bestämningsförhäl-landen under en pä förhand bestämd period, som med avseende pä nämnda första receptor och nämnda andra stämplade receptor är tillräcklig för att immunologiskt binda apoprotein B-100 som finns i provet, varvid en lagrad immunoreaktant i fast fas och vätskefas bildas; (f) nämnda lagrade immunoreaktant i fast fas skiljs frän nämnda vätskefas; och (g) mängden stämplad andra receptor bestäms, som är bunden vid den lagrade immunoreaktanten i fast fas.
19. Kompetitivt förfarande för att bestämma apoprotein B-100 i ett kroppsvätskeprov, kännetecknat av att det omfattar följande steg: (a) det kroppsvätskeprov som skall bestämmas tas; (b) en fast bärare produceras, som omfattar en fast matris, vid vilken dessutom är fästad en pä förhand bestämd mängd reagens apoprotein B-100; (c) väsentligt samtidigt blandas: (i) nämnda kroppsprov; (ii) nämnda fasta bärare, (iii) en pä förhand bestämd mängd receptormolekyler som im-munoreagerar med apoprotein B-100, utsöndrade antingen ur * hybridom med ATCC-depositionsnummer HB 8746 eller ur hybri- li 9271 4 dom med ATCC-depositionsnuinmer HB 8742, varvid en blandning i fast/vätskefas bildas; (d) nämnda blandning hälls i biologiskt bestämda bestäm-ningsförhällanden under en period som med avseende pa recep-tormolekyler är tillräcklig för att immunologiskt bindas vid apoprotein B-100-molekyler i en fast bärare och apoprotein B-100-molekyler i kroppsvätskeprovet och att bilda en immu-noreaktant i fast fas och en immunoreaktant i vätskefas; och (e) nämnda immunoreaktant i fast fas separeras frän nämnda vätskefas; (f) genom att tillsätta i nämnda immunoreaktant i fast fas en biologiskt aktiv andra receptor utförs blandning, vilken andra receptor reagerar med nämnda första receptor, varvid en andra immunoreaktionsblandning i fast/vätskefas bildas, i vilken nämnda andra receptor kopplad tili enzymstämpeln för-mar uttryeka närvaro av nämnda andra receptor i immunoreaktant en; (g) nämnda andra blandning uppehälls en tid som med avseende pä den stämplade andra reeeptorn är tillräcklig för att immunologiskt binda hela den första reeeptorn, som är närva-rande som immunoreaktant i fast form, varvid en lagrad immunoreaktant i fast fas bildas; och (h) den lagrade immunoreaktanten av nämnda fasta fas separeras frän nämnda vätskefas; och (i) mängden stämplad andra receptor bestäms, som bundits vid nämnda lagrade immunoreaktant i fast fas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89365986A | 1986-08-06 | 1986-08-06 | |
| US89365986 | 1986-08-06 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI873410A0 FI873410A0 (sv) | 1987-08-05 |
| FI873410L FI873410L (sv) | 1988-02-07 |
| FI92714B true FI92714B (sv) | 1994-09-15 |
| FI92714C FI92714C (sv) | 1994-12-27 |
Family
ID=25401879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI873410A FI92714C (sv) | 1986-08-06 | 1987-08-05 | Apolipoprotein-B-specifika monoklonala antikroppar producerade av två nya hybridomer |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5330910A (sv) |
| EP (1) | EP0257778B1 (sv) |
| JP (1) | JP2831352B2 (sv) |
| AT (1) | ATE120233T1 (sv) |
| AU (1) | AU7657387A (sv) |
| CA (1) | CA1338032C (sv) |
| DE (1) | DE3751182T2 (sv) |
| DK (1) | DK174932B1 (sv) |
| ES (1) | ES2070820T3 (sv) |
| FI (1) | FI92714C (sv) |
| IE (1) | IE66195B1 (sv) |
| NO (1) | NO172596C (sv) |
| PT (1) | PT85490B (sv) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3734015A1 (de) * | 1987-10-08 | 1989-04-20 | Behringwerke Ag | Diagnostisches mittel und verfahren zur bestimmung von apolipoprotein b |
| JPH07104351B2 (ja) * | 1988-09-29 | 1995-11-13 | 株式会社日本抗体研究所 | 脂質代謝異常検出用キット |
| US5183738A (en) * | 1988-09-29 | 1993-02-02 | Japan Immuno Research Laboratories Co., Ltd. | Kit for the detection of denatured lipoproteins |
| KR950008684A (ko) * | 1993-09-21 | 1995-04-19 | 쇼다 오사무 | 아포리포프로틴 b로 이루어진 엔도텔린 전환효소 |
| US6107045A (en) * | 1994-06-30 | 2000-08-22 | Oklahoma Medical Research Foundation | Antibodies to lipoproteins and apolipoproteins and methods of use thereof |
| JPH1026621A (ja) * | 1996-07-12 | 1998-01-27 | Dai Ichi Pure Chem Co Ltd | イムノアッセイ法 |
| US6506569B1 (en) * | 1997-05-30 | 2003-01-14 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR10 |
| US6716410B1 (en) * | 1999-10-26 | 2004-04-06 | The Regents Of The University Of California | Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| DE60237455D1 (de) * | 2001-07-12 | 2010-10-07 | Kyowa Medex Co Ltd | Verfahren zur quantifizierung von denaturiertem lipoprotein |
| AU2005233361B2 (en) | 2004-04-15 | 2011-02-24 | Athera Biotechnologies Ab | Phosphorylcholine conjugates and corresponding antibodies |
| US7875182B2 (en) * | 2006-11-20 | 2011-01-25 | Cytosorbents, Inc. | Size-selective hemoperfusion polymeric adsorbents |
| US9182389B2 (en) * | 2011-02-22 | 2015-11-10 | Chrome Red Technologies, Llc | Detection of specific antigens in a population of antigens |
| HK1200852A1 (en) | 2011-08-09 | 2015-08-14 | 阿瑟拉生物技术公司 | New antibodies against phosphorylcholine |
| US9796786B2 (en) | 2011-08-09 | 2017-10-24 | Athera Biotechnologies Ab | Antibodies binding to phosphorylcholine (PC) and/or PC conjugates |
| US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
| US10434141B2 (en) | 2016-05-31 | 2019-10-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4486530A (en) * | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| JPS6015559A (ja) * | 1983-07-06 | 1985-01-26 | Shiraimatsu Shinyaku Kk | アポリポ蛋白−ｂの酵素免疫測定試薬 |
| DE3338836A1 (de) * | 1983-10-26 | 1985-05-09 | Boehringer Mannheim Gmbh | Verfahren zur bestimmung der low density lipoproteine (ldl) und reagenz zu seiner durchfuehrung |
| JPS60193926A (ja) * | 1984-03-15 | 1985-10-02 | Tokyo Daigaku | 単クローン性抗ヒトアポリポ蛋白質ｂ１００抗体 |
| EP0209543A4 (en) * | 1984-12-31 | 1989-07-11 | Internat Genetic Engineering I | FRAGMENTS OF HUMAN APOLIPOPROTEINS PEPTIDES, TYPE-SPECIFIC ANTIBODIES AND METHODS OF USE. |
| US4677057A (en) * | 1985-03-11 | 1987-06-30 | Scripps Clinic And Research Foundation | Diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins |
| US4828986A (en) * | 1986-09-29 | 1989-05-09 | Scripps Clinic And Research Foundation | Assay method and diagnostic system for determining the ratio of APO B-100 to APO A-I in a blood sample |
-
1987
- 1987-07-20 AT AT87306413T patent/ATE120233T1/de not_active IP Right Cessation
- 1987-07-20 DE DE3751182T patent/DE3751182T2/de not_active Expired - Lifetime
- 1987-07-20 EP EP87306413A patent/EP0257778B1/en not_active Expired - Lifetime
- 1987-07-20 ES ES87306413T patent/ES2070820T3/es not_active Expired - Lifetime
- 1987-08-04 AU AU76573/87A patent/AU7657387A/en not_active Abandoned
- 1987-08-05 IE IE210487A patent/IE66195B1/en not_active IP Right Cessation
- 1987-08-05 CA CA000543750A patent/CA1338032C/en not_active Expired - Fee Related
- 1987-08-05 NO NO873271A patent/NO172596C/no not_active IP Right Cessation
- 1987-08-05 PT PT85490A patent/PT85490B/pt unknown
- 1987-08-05 DK DK198704079A patent/DK174932B1/da not_active IP Right Cessation
- 1987-08-05 FI FI873410A patent/FI92714C/sv not_active IP Right Cessation
- 1987-08-06 JP JP62197250A patent/JP2831352B2/ja not_active Expired - Lifetime
-
1989
- 1989-09-27 US US07/415,432 patent/US5330910A/en not_active Expired - Lifetime
-
1994
- 1994-03-30 US US08/219,963 patent/US5460947A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE3751182D1 (de) | 1995-04-27 |
| ATE120233T1 (de) | 1995-04-15 |
| EP0257778A2 (en) | 1988-03-02 |
| DK174932B1 (da) | 2004-03-01 |
| DE3751182T2 (de) | 1995-10-26 |
| FI873410A0 (sv) | 1987-08-05 |
| US5460947A (en) | 1995-10-24 |
| CA1338032C (en) | 1996-02-06 |
| JP2831352B2 (ja) | 1998-12-02 |
| EP0257778A3 (en) | 1990-03-21 |
| NO873271L (no) | 1988-02-08 |
| IE872104L (en) | 1988-02-06 |
| IE66195B1 (en) | 1995-12-13 |
| FI873410L (sv) | 1988-02-07 |
| AU7657387A (en) | 1988-02-11 |
| DK407987D0 (da) | 1987-08-05 |
| FI92714C (sv) | 1994-12-27 |
| ES2070820T3 (es) | 1995-06-16 |
| JPS63279783A (ja) | 1988-11-16 |
| NO172596C (no) | 1993-08-11 |
| PT85490A (en) | 1987-09-01 |
| EP0257778B1 (en) | 1995-03-22 |
| DK407987A (da) | 1988-02-07 |
| US5330910A (en) | 1994-07-19 |
| NO873271D0 (no) | 1987-08-05 |
| PT85490B (pt) | 1990-06-29 |
| NO172596B (no) | 1993-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI92714B (sv) | Apolipoprotein-B-specifika monoklonala antikroppar producerade av två nya hybridomer | |
| FI89214B (fi) | Analysfoerfarande och diagnostiskt system foer ett markerande aemne foer abnorm lipidmetabolism | |
| JP2505218B2 (ja) | アポリポタンパクａ―１に対して特異性を有するモノクロ―ナル抗体又はそのパラト―プ含有ポリペプチド部分並びにそれを使用する診断装置 | |
| US4677057A (en) | Diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins | |
| US5814467A (en) | APO AI polypeptides, diagnostic methods and systems for quantifying APO AI, and therapeutic methods | |
| JP2765902B2 (ja) | アポａｉの定量のための診断法及び診断システム | |
| IE881290L (en) | Monoclonal antibodies for the selective immunological¹determination of intact procollagen peptide (Type III) and¹procollagen (Type III) in body fluids | |
| WO1991018619A1 (en) | Apo ai polypeptides, antibodies, and immunoassays | |
| US5747652A (en) | Antibody to smooth muscle myosin heavy chains | |
| EP0364560A1 (en) | Diagnostic methods and systems for quantifying apo ai | |
| AU621575B2 (en) | Diagnostic methods and systems for quantifying apo ai | |
| JP2000060551A (ja) | 抗プリオン抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application lapsed | ||
| BB | Publication of examined application | ||
| FG | Patent granted |
Owner name: SCRIPPS CLINIC AND RESEARCH FOUNDATION |
|
| MA | Patent expired |